


Damora Therapeutics, Inc. (DMRA)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001800315

Damora Therapeutics, Inc. DMRA; healthcare		
Grade	None 5 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it  \$20 Nov Jan Mar May Jul Sep \$20.56
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025	
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$120M to \$591M assets total assets \$260.5M	
Warnings	dilution, thin data not computable: degenerate inputs, distress, fortress balance sheet	
Inputs computable	5 of 14	
Graded from	filings received through Mar 19, 2026 204 days before the rescan; latest periodic filing 10-Q received Aug 10, 2026	
Last close	\$20.58 2026-10-08; market equity \$1.3B	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 19, 2026

We are a biopharmaceutical company developing therapies for the treatment of hematologic disorders. In our previously announced Asset Acquisition (as defined below), we bolstered our pipeline with the addition of three product candidates designed to treat myeloproliferative neoplasms ("MPNs"), a group of related, chronic disorders of the bone marrow. Our lead product candidate, DMR-001, targets mutant forms of the calcium binding protein calreticulin ("CALR"), which are collectively known as mutCALR. We have exercised our Option to license exclusive worldwide development and commercialization rights to DMR-001 from Paragon Therapeutics, Inc.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 3.5						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(146.3%)	(6.6%)	3.5	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 12.0						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		7.04	(0.31)	13.9	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		12.98x	2.96x	10.0	839	2025-12-31
Growth and financing, sleeve percentile 52.8						
Revenue growth, three-year compound		not computable	10.0%			four annual observations are required; found 0
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 2
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		52.7%	2.1%	7.1	704	2025-12-31
Net share issuance, one year		4,460.3%	2.5%	98.4	634	2026-03-17

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 4460.3%
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	657.5%	8.0%	100
Distance from 52-week high	(39.8%)	(31.4%)	39
EBIT to enterprise value	not computable	(1.5%)	

Free cash flow yield	(3.4%)	(1.0%)	44
Book value to price	0.41	0.28	62
Sales to price	not computable	0.31	
Composite equity issuance, five years	411.2%	20.3%	97
Relative strength against the sector, log excess return	1.81	(0.14)	100

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$540.5M
Operating cash flow, four quarters	-\$44.5M
Months of runway	145.7
Days since last periodic filing	60 (10-Q received Aug 10, 2026)
Median daily dollar volume, 63 sessions	\$11.3M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$209.8M	2025-12-31	2026-03-19	10-K	0001193125-26-115922
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$6.7M	2025-12-31	2026-03-19	10-K	0001193125-26-115922
3	assets	us-gaap:Assets	\$260.5M	2025-12-31	2026-03-19	10-K	0001193125-26-115922
4	assets	us-gaap:Assets	\$17.1M	2024-12-31	2026-03-19	10-K	0001193125-26-115922
5	current assets	us-gaap:AssetsCurrent	\$260.4M	2025-12-31	2026-03-19	10-K	0001193125-26-115922
6	current liabilities	us-gaap:LiabilitiesCurrent	\$20.1M	2025-12-31	2026-03-19	10-K	0001193125-26-115922
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$487.4M	2025-12-31	2026-03-19	10-K	0001193125-26-115922
8	operating income	us-gaap:OperatingIncomeLoss	-\$210.9M	2025-12-31	2026-03-19	10-K	0001193125-26-115922
9	book equity	us-gaap:StockholdersEquity	\$240.4M	2025-12-31	2026-03-19	10-K	0001193125-26-115922
10	liabilities	us-gaap:Liabilities	\$20.1M	2025-12-31	2026-03-19	10-K	0001193125-26-115922
11	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$196,000	2022-12-31	2024-03-08	10-K	0000950170-24-028610
12	depreciation amortization	us-gaap:Depreciation	\$42,000	2022-12-31	2024-03-08	10-K	0000950170-24-028610
13	operating income	us-gaap:OperatingIncomeLoss	-\$61.2M	2022-12-31	2024-03-08	10-K	0000950170-24-028610
14	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$11.6M	2022-12-31	2024-03-08	10-K	0000950170-24-028610
15	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2022-12-31	2024-03-08	10-K	0000950170-24-028610
16	current assets	us-gaap:AssetsCurrent	\$63.9M	2022-12-31	2024-03-08	10-K	0000950170-24-028610
17	current liabilities	us-gaap:LiabilitiesCurrent	\$11.1M	2022-12-31	2024-03-08	10-K	0000950170-24-028610
18	current assets	us-gaap:AssetsCurrent	\$110.1M	2021-12-31	2023-03-09	10-K	0000950170-23-006807
19	current liabilities	us-gaap:LiabilitiesCurrent	\$4.5M	2021-12-31	2023-03-09	10-K	0000950170-23-006807
20	assets	us-gaap:Assets	\$38.2M	2023-12-31	2025-03-19	10-K	0000950170-25-041981
21	assets	us-gaap:Assets	\$73.2M	2022-12-31	2024-03-08	10-K	0000950170-24-028610
22	shares outstanding	dei:EntityCommonStockSharesOutstanding	60,303,212	2026-03-17	2026-03-19	10-K	0001193125-26-115922
23	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,322,359	2025-03-14	2025-03-19	10-K	0000950170-25-041981